All patients
Age > 65y Asian type ECOG 0 ECOG 1 metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) metastasis (lung) metastasis (lymph node ) PD-L1 < 1% PD-L1 > 1% stage II stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
breast cancer (BC), atezolizumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpassion-031 (all population), 2020 0.69 [0.25; 1.89]
IMpassion-130 (all population), 2018 0.86 [0.72; 1.02]
IMpassion-130 (PDL1>1%), 2018 0.71 [0.54; 0.94]
0.81 [0.70 ; 0.94 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018 3 0% 1,604 low not evaluable PFS (extension)detailed results IMpassion-130 (all population), 2018 0.80 [0.69; 0.92]
IMpassion-130 (PDL1>1%), 2018 0.63 [0.50; 0.80]
0.72 [0.57 ; 0.91 ] IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018 2 65% 1,271 low not evaluable progression or deaths (PFS)detailed results IMpassion-130 (all population), 2018 0.80 [0.69; 0.92]
IMpassion-130 (PDL1>1%), 2018 0.62 [0.49; 0.78]
0.72 [0.56 ; 0.92 ] IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018 2 70% 1,271 low not evaluable DORdetailed results IMpassion-130 (all population), 2018 0.78 [0.63; 0.97]
IMpassion-130 (PDL1>1%), 2018 0.60 [0.42; 0.85]
0.71 [0.55 ; 0.91 ] IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018 2 36% 369 low not evaluable events or deaths (EFS)detailed results IMpassion-031 (all population), 2020 0.76 [0.40; 1.44]
0.76 [0.40 ; 1.44 ] IMpassion-031 (all population), 2020 1 0% 333 NA not evaluable objective responses (ORR)detailed results IMpassion-130 (all population), 2018 1.52 [1.17; 1.98]
IMpassion-130 (PDL1>1%), 2018 1.96 [1.29; 2.98]
1.64 [1.31 ; 2.05 ] IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018 2 1% 1,271 low not evaluable pCR detailed results IMpassion-031 (all population), 2020 1.95 [1.26; 3.01]
IMpassion-031 (PDL1>1%), 2020 2.23 [1.16; 4.30]
2.03 [1.41 ; 2.92 ] IMpassion-031 (all population), 2020, IMpassion-031 (PDL1>1%), 2020 2 0% 487 low not evaluable AE (any grade)detailed results IMpassion-031 (all population), 2020 0.49 [0.02; 14.69]
IMpassion-130 (all population), 2018 3.15 [0.85; 11.73]
2.47 [0.72 ; 8.47 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.10 [0.71; 1.72]
IMpassion-130 (all population), 2018 1.31 [1.00; 1.70]
1.25 [1.00 ; 1.57 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable AE leading to death (grade 5)detailed results IMpassion-031 (all population), 2020 1.02 [0.06; 16.42]
IMpassion-130 (all population), 2018 1.94 [0.48; 7.81]
1.71 [0.49 ; 5.92 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpassion-031 (all population), 2020 1.18 [0.70; 2.01]
IMpassion-130 (all population), 2018 2.24 [1.46; 3.43]
1.66 [0.89 ; 3.11 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 71% 1,221 low not evaluable SAE (any grade)detailed results IMpassion-031 (all population), 2020 2.00 [1.20; 3.36]
IMpassion-130 (all population), 2018 1.33 [0.96; 1.84]
1.55 [1.05 ; 2.29 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 43% 1,221 low not evaluable STRAE (any grade)detailed results IMpassion-031 (all population), 2020 1.58 [0.91; 2.75]
IMpassion-130 (all population), 2018 1.82 [1.16; 2.87]
1.72 [1.21 ; 2.45 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable TRAE (any grade)detailed results IMpassion-031 (all population), 2020 0.98 [0.14; 7.05]
IMpassion-130 (all population), 2018 1.80 [0.96; 3.39]
1.70 [0.93 ; 3.11 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.15 [0.74; 1.77]
IMpassion-130 (all population), 2018 1.52 [1.15; 2.01]
1.39 [1.08 ; 1.80 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 13% 1,221 low not evaluable TRAE leading to death (grade 5)detailed results IMpassion-130 (all population), 2018 2.91 [0.30; 28.05]
2.91 [0.30 ; 28.05 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Diabetes TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.51 [0.02 ; 15.24 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.06; 16.42]
1.02 [0.06 ; 16.42 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Rash TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.32; 3.23]
1.02 [0.32 ; 3.23 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.06; 15.47]
0.96 [0.06 ; 15.47 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
IMpassion-130 (all population), 2018 1.93 [0.17; 21.40]
1.24 [0.17 ; 8.82 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Acute kidney injury AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Adrenal insufficiency AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Alopecia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 1.93 [0.17; 21.40]
1.62 [0.21 ; 12.61 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Anaemia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.21 [0.54; 2.69]
IMpassion-130 (all population), 2018 1.04 [0.48; 2.24]
1.12 [0.64 ; 1.94 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Arthralgia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 0.96 [0.06; 15.47]
0.98 [0.10 ; 9.47 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Asthenia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.54 [0.25; 9.32]
IMpassion-130 (all population), 2018 0.72 [0.16; 3.24]
0.98 [0.31 ; 3.12 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Back pain AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 2.92 [0.59; 14.54]
2.51 [0.57 ; 11.10 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Cardiomyopathy AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Chills AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Colitis AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.06; 15.47]
0.96 [0.06 ; 15.47 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Constipation AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
IMpassion-130 (all population), 2018 2.91 [0.30; 28.05]
1.70 [0.26 ; 11.21 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Cough AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.99 [0.06 ; 15.89 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Decreased appetite AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 0.96 [0.19; 4.80]
0.97 [0.22 ; 4.30 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Diarrhoea AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 4.15 [0.46; 37.53]
IMpassion-130 (all population), 2018 0.85 [0.33; 2.24]
1.36 [0.33 ; 5.60 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 40% 1,221 low not evaluable Dizziness AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.96 [0.02 ; 48.73 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Dry skin AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Dysgeusia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.99 [0.06 ; 15.89 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Dyspepsia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Dysphonia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.14; 7.32]
IMpassion-130 (all population), 2018 0.96 [0.19; 4.80]
0.99 [0.28 ; 3.42 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Epistaxis AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Fatigue AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.23 [0.37; 4.11]
IMpassion-130 (all population), 2018 1.10 [0.54; 2.22]
1.13 [0.61 ; 2.08 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.25 [0.61; 2.57]
1.25 [0.61 ; 2.57 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Headache AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
IMpassion-130 (all population), 2018 0.48 [0.09; 2.63]
0.49 [0.11 ; 2.23 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Hypertension AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.84 [0.35; 2.00]
IMpassion-130 (all population), 2018 0.35 [0.11; 1.09]
0.59 [0.25 ; 1.38 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 31% 1,221 low not evaluable Hyperthyroidism AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.96 [0.02 ; 48.73 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Increase AST AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.44 [0.62; 9.59]
IMpassion-130 (all population), 2018 0.96 [0.38; 2.45]
1.33 [0.56 ; 3.16 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 17% 1,221 low not evaluable Increased ALT AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.91 [0.36; 2.30]
IMpassion-130 (all population), 2018 1.55 [0.50; 4.79]
1.13 [0.55 ; 2.31 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.06; 16.42]
1.02 [0.06 ; 16.42 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Lacrimation increased AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.86 [0.76; 4.55]
IMpassion-130 (all population), 2018 1.55 [0.50; 4.79]
1.73 [0.86 ; 3.49 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Mucosal inflammation AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
IMpassion-130 (all population), 2018 1.94 [0.35; 10.63]
1.96 [0.43 ; 8.98 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Myalgia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
IMpassion-130 (all population), 2018 0.64 [0.11; 3.86]
0.83 [0.17 ; 4.04 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Myopathy AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Nausea AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.28 [0.06; 1.38]
IMpassion-130 (all population), 2018 0.60 [0.19; 1.84]
0.47 [0.19 ; 1.17 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Neutropenia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.10 [0.65; 1.84]
IMpassion-130 (all population), 2018 1.02 [0.63; 1.64]
1.05 [0.74 ; 1.50 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Oropharyngeal pain AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Paraesthesia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 1.93 [0.17; 21.40]
1.62 [0.21 ; 12.61 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Pericarditis AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.40 [0.08; 2.09]
IMpassion-130 (all population), 2018 2.07 [1.03; 4.17]
1.09 [0.23 ; 5.23 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 69% 1,221 low not evaluable Peripheral oedema AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
IMpassion-130 (all population), 2018 0.16 [0.02; 1.33]
0.22 [0.04 ; 1.33 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.28 [0.34; 4.86]
1.28 [0.34 ; 4.86 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Pneumonia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 3.27 [0.89; 11.95]
3.27 [0.89 ; 11.95 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Pneumonitis AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 3.87 [0.17; 86.09]
3.87 [0.17 ; 86.09 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Pruritus AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.25 [0.03; 2.26]
IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.35 [0.05 ; 2.36 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Pyrexia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 4.11 [0.18; 91.86]
IMpassion-130 (all population), 2018 5.82 [0.29; 116.53]
4.92 [0.57 ; 42.55 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Rash AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 4.15 [0.46; 37.53]
IMpassion-130 (all population), 2018 0.96 [0.14; 6.88]
1.84 [0.43 ; 7.98 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Sepsis AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.16 [0.01; 3.20]
0.16 [0.01 ; 3.20 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Stomatitis AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 6.20 [0.31; 124.85]
IMpassion-130 (all population), 2018 0.96 [0.06; 15.47]
2.27 [0.30 ; 17.45 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.17; 21.40]
1.93 [0.17 ; 21.40 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Vomiting AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.05 [0.18; 22.82]
IMpassion-130 (all population), 2018 0.77 [0.21; 2.89]
0.97 [0.30 ; 3.07 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Weight decreased AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 5.82 [0.29; 116.53]
5.82 [0.29 ; 116.53 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-02 11:25 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866
